



October 30<sup>th</sup>, 2017 - Tampere, Finland  
FOR IMMEDIATE RELEASE

## **Dr. Rami Lehtinen nominated as CEO**

### **Injeq is shifting gears for market entry in summer 2018**

Following the successful crowdfunding share issue in the second quarter of 2017 Injeq has shifted its focus from R&D to market entry. Three key elements are contributing to this target; the company is building up its production capacity in Tampere, ramping up the sales function and working rigorously towards CE approval for Injeq IQ-Needle™ product family. At the same time clinical trials are expanding to Sweden, Norway and Denmark.

Changing the operating mode of the company is a pivotal point, in which it is natural to change the captain of the boat as well. Kai Kronström has successfully led the company since its inception in December 2010. Kai is now handing the rudder over to Dr. Rami Lehtinen who has been VP Clinical Development & Sales in Injeq since January 2017.

*"Kai together with the whole team has done tremendous work in taking us from day one to this point when we have a product ready to be introduced to the market. And now, it is a pleasant challenge for me to take our product into production and out to the market, where it can be used to improve patient safety and treatment outcome",* says Dr. Rami Lehtinen, CEO of Injeq.

*"With funding from the successful crowdfunding share issue last summer Injeq is changing its key focus from R&D to market entry. At this stage it feels natural to also change the person at the helm of the company. Rami is a perfect choice to take us to the next level",* says Dr. Tommi Rasila, Chairman of Injeq.

Kai Kronström, one of the founders, will continue to work for Injeq with focus on the processes critical for timely market entry, such as the CE mark and product approvals.

Earlier this fall also the chairman of the board was changed when Chairman and Founder Prof. Jari Hyttinen took a position abroad. He was superseded by Dr. Tommi Rasila, who has been serving as the Vice-Chairman since fall 2016.

For further information meet Injeq at jENS 2017 in Venice or contact:

- Rami Lehtinen, CEO, +358 50 528 7012, [rami.lehtinen@injeq.com](mailto:rami.lehtinen@injeq.com)
- Tommi Rasila, Chairman of the Board, +358 40 750 8158, [tommi.rasila@injeq.com](mailto:tommi.rasila@injeq.com)
- Photographs can be downloaded from <https://injeq.com/media/>

### ***Injeq in brief:***

*Injeq is a medical device company based in Tampere, Finland. The company is devoted to developing and commercializing real-time bioimpedance based tissue identification. It has announced the first product currently in clinical trials; Injeq IQ-Needle™. Commercial availability for first products is planned for summer 2018. The technology can be applied for multiple clinical applications, including regional anesthesia, lumbar punctures, biopsy and intratumoral drug delivery. The products are expected to benefit the patients by improving diagnosis, reducing complications and enabling new type of treatments.*

***Injeq IQ-Needle™ – The smart needle that knows where its tip is.***